RELIABILITY OF THE DISEASE SEVERITY MEASURES AND THE RELIABILITY OF THE HEALTH RELATED QUALITY OF LIFE MEASURES OF THE PEOPLE WITH PSORIASIS

Z. Sojević-Timotijević ,
Z. Sojević-Timotijević

Dermatovenerology Clinic, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

P. Majcan ,
P. Majcan

Clinic Department of Dermatovenerology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

N. Dostanić ,
N. Dostanić

Clinic Department of Dermatovenerology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

S. Perišić ,
S. Perišić

Clinic Department of Dermatovenerology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

M. Relić ,
M. Relić

Dermatovenerology Clinic, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

A. Ilić
A. Ilić

Institute of Medical Statistics and Informatics, Medical faculty Priština , Kosovska Mitrovica , Kosovo*

Published: 01.01.2010.

Volume 38, Issue 1 (2010)

pp. 83-86;

https://doi.org/10.70949/pramed201001331S

Abstract

The objective of this study that included 34 patients with psoriasis was to assess the reliability of the disease severity measures (i.e. Psoriasis Area and Severity Index - PASI) and the reliability of the health related quality of life measures (i.e. EuroQol EQ-5D Quality of Life Scale - EQ-5D, Dermatology Life Quality Index - DLQI and Psoriasis Disability Index -PDI). High interobserver correlation reliability and good test-retest reliability of PASI scores, as well as good test-retest reliability of EQ-5D, DLQI and PDI scores were achieved. Correlation coefficients between the test and retest scores on DLQI and PDI were higher than those on the dimensions and on EQ-VAS in EQ-5D. Disease severity scores given by PASI and the quality of lify scores given by EQ-5D, DLQI and PDI offered the reliable assessment of both the psoriasis severity and the quality of life of the people with psoriasis.

Keywords

References

1.
Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol. 12:8–11.
2.
Badia X, Mascaró JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability, and sensitivity to change of the DLQI. The Cavide Research Group Br J Dermatol. 141:698–702.
3.
Shierar R, Willian MK, O’Donnel MM, Thompson CS, Revice DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 4(71).
4.
Kerkhof PC. On the limitations of the psoriasis area and severity index (PASI. Br J Dermatol. 126(205).
5.
Measuring severity of psoriasis: methodological issues. J Dermatol Treat. 7:119–24.
6.
Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 124:565–70.
7.
Kirby B, Fortune DG, Bhushan M. The Salford Psoriasis Index: a holistic measure of psoriasis severity. Br J Dermatol. 142:728–32.
8.
Food, Administration D. Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Draft.
9.
Smith CH, Anstey AV, Barker JN, Borden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 153:486–97.
10.
Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 41:401–7.
11.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 19:210–6.
12.
JE W, CD S. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care. 30:473–83.
13.
Group E. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 16:199–208.
14.
Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychological measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 45:72–6.
15.
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 210:194–9.
16.
Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 157:238–44.
17.
Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 141:185–91.
18.
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 54:685–704.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by